Spots Global Cancer Trial Database for GW572016 In Patients With Advanced Or Metastatic Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: GW572016 In Patients With Advanced Or Metastatic Breast Cancer
Official Title: Phase II Clinical Study of GW572016 in Patients With Advanced or Metastatic Breast Cancer
Study ID: NCT00462956
Conditions
Interventions
Study Description
Brief Summary: This study is designed to evaluate the efficacy and safety of GW572016 in patients with refractory breast cancer and consists of two cohorts of patients. Patients in Cohort A must have ErbB2 overexpressing tumors while patients in Cohort B must have non-ErbB2 overexpressing tumors. Patients eligible for this study must have advanced metastatic breast cancer who have previously received treatment with anthracycline and taxane.
Detailed Description:
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
GSK Investigational Site, Ehime, , Japan
GSK Investigational Site, Fukuoka, , Japan
GSK Investigational Site, Kanagawa, , Japan
GSK Investigational Site, Saitama, , Japan
GSK Investigational Site, Tochigi, , Japan
GSK Investigational Site, Tokyo, , Japan
GSK Investigational Site, Tokyo, , Japan
GSK Investigational Site, Tokyo, , Japan
GSK Investigational Site, , ,
Contact Details
Name: GSK Clinical Trials
Affiliation: GlaxoSmithKline
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
